In the first long-term follow-up of patients treated with buprenorphine/naloxone for addiction to opioid pain relievers, half reported that they were abstinent from the drugs 18 months after starting the therapy.
Can marijuana use put offspring at heightened risk for opiate addiction, even if the use stops before the offspring are conceived? Results from a recent NIDA-funded study are consistent with other studies suggesting that a parent’s history of drug use, even preconception, may affect a child’s brain function and behavior.
Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.
Exposing rats to THC increases the likelihood that the animals will later self-administer nicotine. THC-exposed rats are also willing to work harder to obtain nicotine. When extrapolated to people, the findings suggest that THC’s pharmacological impact on the brain may make a person who uses marijuana more vulnerable to developing nicotine addiction, an underappreciated health consequence of marijuana use.
Almost one-third (32 percent) of the roughly 42,000 Monitoring the Future survey respondents reported having used marijuana during their lifetime. However, abuse of many other drugs—methamphetamine, heroin, cocaine, and some prescription medications—declined.
More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.
Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.